Concepts (172)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genetic Testing | 36 | 2025 | 40 | 4.020 |
Why?
|
| Genetic Predisposition to Disease | 30 | 2025 | 44 | 3.590 |
Why?
|
| Genetic Variation | 25 | 2025 | 31 | 3.400 |
Why?
|
| Breast Neoplasms | 18 | 2025 | 144 | 2.550 |
Why?
|
| Germ-Line Mutation | 23 | 2025 | 24 | 2.240 |
Why?
|
| Tumor Suppressor Protein p53 | 13 | 2025 | 23 | 1.700 |
Why?
|
| Humans | 57 | 2025 | 4931 | 1.260 |
Why?
|
| Neoplasms | 9 | 2025 | 66 | 1.250 |
Why?
|
| BRCA1 Protein | 10 | 2025 | 10 | 1.180 |
Why?
|
| Mutation, Missense | 10 | 2025 | 14 | 0.970 |
Why?
|
| Li-Fraumeni Syndrome | 6 | 2023 | 6 | 0.950 |
Why?
|
| Sequence Analysis, DNA | 6 | 2020 | 14 | 0.940 |
Why?
|
| Genome, Human | 8 | 2024 | 8 | 0.930 |
Why?
|
| BRCA2 Protein | 8 | 2025 | 8 | 0.840 |
Why?
|
| Adenomatous Polyposis Coli | 4 | 2024 | 4 | 0.810 |
Why?
|
| Fanconi Anemia Complementation Group N Protein | 7 | 2025 | 7 | 0.770 |
Why?
|
| Genetic Association Studies | 6 | 2021 | 7 | 0.740 |
Why?
|
| Ovarian Neoplasms | 6 | 2024 | 34 | 0.730 |
Why?
|
| Female | 26 | 2025 | 2964 | 0.700 |
Why?
|
| Databases, Genetic | 7 | 2025 | 8 | 0.600 |
Why?
|
| Biomarkers, Tumor | 5 | 2021 | 30 | 0.590 |
Why?
|
| PTEN Phosphohydrolase | 3 | 2024 | 5 | 0.570 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2025 | 16 | 0.510 |
Why?
|
| Checkpoint Kinase 2 | 5 | 2025 | 5 | 0.480 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 4 | 2025 | 6 | 0.470 |
Why?
|
| Phenotype | 9 | 2025 | 62 | 0.420 |
Why?
|
| Adenomatous Polyposis Coli Protein | 2 | 2024 | 2 | 0.400 |
Why?
|
| Mutation | 8 | 2022 | 51 | 0.400 |
Why?
|
| High-Throughput Nucleotide Sequencing | 8 | 2019 | 14 | 0.390 |
Why?
|
| DNA-Binding Proteins | 3 | 2023 | 26 | 0.390 |
Why?
|
| Neoplastic Syndromes, Hereditary | 3 | 2025 | 3 | 0.390 |
Why?
|
| Computational Biology | 6 | 2025 | 8 | 0.390 |
Why?
|
| Adult | 12 | 2025 | 1402 | 0.380 |
Why?
|
| Middle Aged | 12 | 2025 | 1544 | 0.360 |
Why?
|
| Genes, p53 | 2 | 2021 | 4 | 0.330 |
Why?
|
| Penetrance | 3 | 2025 | 3 | 0.330 |
Why?
|
| RNA Splice Sites | 4 | 2022 | 4 | 0.320 |
Why?
|
| Genomics | 6 | 2024 | 9 | 0.290 |
Why?
|
| Carcinoma, Ductal, Breast | 3 | 2025 | 6 | 0.290 |
Why?
|
| Case-Control Studies | 6 | 2025 | 70 | 0.270 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 3 | 2021 | 4 | 0.270 |
Why?
|
| Alleles | 6 | 2023 | 11 | 0.260 |
Why?
|
| Computer Simulation | 3 | 2020 | 23 | 0.250 |
Why?
|
| Fumarate Hydratase | 1 | 2025 | 1 | 0.250 |
Why?
|
| Leiomyomatosis | 1 | 2025 | 1 | 0.250 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2025 | 2 | 0.250 |
Why?
|
| Kidney Neoplasms | 1 | 2025 | 3 | 0.250 |
Why?
|
| Genes, BRCA2 | 2 | 2022 | 2 | 0.240 |
Why?
|
| Germ Cells | 5 | 2024 | 6 | 0.240 |
Why?
|
| Alternative Splicing | 3 | 2022 | 3 | 0.240 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2025 | 2 | 0.230 |
Why?
|
| Aged | 7 | 2025 | 1188 | 0.230 |
Why?
|
| RNA | 2 | 2022 | 18 | 0.210 |
Why?
|
| DNA Mismatch Repair | 2 | 2021 | 4 | 0.210 |
Why?
|
| Bayes Theorem | 2 | 2023 | 21 | 0.200 |
Why?
|
| United States | 6 | 2023 | 764 | 0.200 |
Why?
|
| Stomach Neoplasms | 1 | 2022 | 7 | 0.200 |
Why?
|
| Cohort Studies | 5 | 2021 | 224 | 0.190 |
Why?
|
| DNA Glycosylases | 1 | 2022 | 1 | 0.190 |
Why?
|
| Succinate Dehydrogenase | 1 | 2021 | 1 | 0.190 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2021 | 2 | 0.190 |
Why?
|
| Carcinoma, Lobular | 1 | 2021 | 1 | 0.190 |
Why?
|
| Societies, Medical | 2 | 2018 | 56 | 0.180 |
Why?
|
| Recombinational DNA Repair | 1 | 2021 | 1 | 0.180 |
Why?
|
| Endometrial Neoplasms | 1 | 2021 | 23 | 0.180 |
Why?
|
| Genes, APC | 1 | 2020 | 1 | 0.170 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2020 | 3 | 0.170 |
Why?
|
| Laboratories | 2 | 2017 | 3 | 0.170 |
Why?
|
| Prognosis | 4 | 2021 | 167 | 0.170 |
Why?
|
| Guidelines as Topic | 2 | 2020 | 15 | 0.160 |
Why?
|
| Practice Guidelines as Topic | 1 | 2020 | 69 | 0.160 |
Why?
|
| Gene Duplication | 2 | 2018 | 2 | 0.160 |
Why?
|
| Tandem Repeat Sequences | 1 | 2018 | 1 | 0.150 |
Why?
|
| Publications | 1 | 2018 | 3 | 0.150 |
Why?
|
| Direct-To-Consumer Screening and Testing | 1 | 2018 | 2 | 0.150 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2018 | 9 | 0.150 |
Why?
|
| Nuclear Proteins | 1 | 2017 | 9 | 0.140 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2017 | 6 | 0.140 |
Why?
|
| Clinical Laboratory Information Systems | 1 | 2017 | 1 | 0.140 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2017 | 5 | 0.140 |
Why?
|
| RNA Splicing | 3 | 2023 | 4 | 0.140 |
Why?
|
| Male | 5 | 2025 | 2620 | 0.130 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2015 | 1 | 0.120 |
Why?
|
| MutL Protein Homolog 1 | 3 | 2021 | 4 | 0.120 |
Why?
|
| Intestinal Polyposis | 1 | 2015 | 1 | 0.120 |
Why?
|
| Pseudogenes | 1 | 2015 | 2 | 0.120 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2015 | 2 | 0.120 |
Why?
|
| Smad4 Protein | 1 | 2015 | 2 | 0.120 |
Why?
|
| Telangiectasia, Hereditary Hemorrhagic | 1 | 2015 | 2 | 0.120 |
Why?
|
| Gene Deletion | 1 | 2015 | 7 | 0.120 |
Why?
|
| Young Adult | 3 | 2021 | 382 | 0.110 |
Why?
|
| Exons | 3 | 2020 | 6 | 0.110 |
Why?
|
| Risk Factors | 3 | 2025 | 593 | 0.110 |
Why?
|
| Software | 3 | 2018 | 16 | 0.110 |
Why?
|
| Algorithms | 2 | 2024 | 69 | 0.100 |
Why?
|
| DNA | 2 | 2024 | 18 | 0.090 |
Why?
|
| Gene Frequency | 2 | 2023 | 3 | 0.090 |
Why?
|
| Medical History Taking | 2 | 2021 | 7 | 0.090 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 202 | 0.090 |
Why?
|
| Genotype | 2 | 2020 | 18 | 0.080 |
Why?
|
| Age of Onset | 2 | 2021 | 12 | 0.080 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 407 | 0.080 |
Why?
|
| Adolescent | 2 | 2021 | 569 | 0.080 |
Why?
|
| Odds Ratio | 2 | 2020 | 67 | 0.080 |
Why?
|
| Mismatch Repair Endonuclease PMS2 | 2 | 2019 | 2 | 0.080 |
Why?
|
| MutS Homolog 2 Protein | 2 | 2019 | 2 | 0.080 |
Why?
|
| Sequence Alignment | 2 | 2020 | 4 | 0.070 |
Why?
|
| DNA Mutational Analysis | 2 | 2016 | 8 | 0.060 |
Why?
|
| Genes, Neoplasm | 1 | 2024 | 1 | 0.060 |
Why?
|
| Mice | 2 | 2022 | 555 | 0.050 |
Why?
|
| Exome | 1 | 2023 | 1 | 0.050 |
Why?
|
| North America | 1 | 2023 | 7 | 0.050 |
Why?
|
| Adenosine Triphosphate | 1 | 2023 | 11 | 0.050 |
Why?
|
| Cadherins | 1 | 2022 | 1 | 0.050 |
Why?
|
| Antigens, CD | 1 | 2022 | 16 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2022 | 127 | 0.050 |
Why?
|
| Heterozygote | 1 | 2022 | 3 | 0.050 |
Why?
|
| Virulence | 1 | 2021 | 4 | 0.050 |
Why?
|
| Datasets as Topic | 1 | 2021 | 4 | 0.050 |
Why?
|
| Chromosome Mapping | 1 | 2001 | 9 | 0.050 |
Why?
|
| Animals | 2 | 2022 | 1369 | 0.050 |
Why?
|
| Data Collection | 1 | 2021 | 27 | 0.050 |
Why?
|
| Bile Acids and Salts | 1 | 2001 | 8 | 0.050 |
Why?
|
| Hypercholesterolemia | 1 | 2001 | 11 | 0.050 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 93 | 0.050 |
Why?
|
| Structure-Activity Relationship | 1 | 2021 | 7 | 0.040 |
Why?
|
| Genetic Heterogeneity | 1 | 2020 | 1 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2020 | 11 | 0.040 |
Why?
|
| Databases, Protein | 1 | 2020 | 1 | 0.040 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2020 | 5 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2020 | 2 | 0.040 |
Why?
|
| Evolution, Molecular | 1 | 2020 | 3 | 0.040 |
Why?
|
| Amino Acid Sequence | 1 | 2020 | 31 | 0.040 |
Why?
|
| Phylogeny | 1 | 2020 | 15 | 0.040 |
Why?
|
| Receptor, ErbB-2 | 1 | 2020 | 16 | 0.040 |
Why?
|
| Survival Rate | 1 | 2020 | 92 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 12 | 0.040 |
Why?
|
| Disease Management | 1 | 2020 | 23 | 0.040 |
Why?
|
| Genes, BRCA1 | 1 | 2019 | 1 | 0.040 |
Why?
|
| Decision Making | 1 | 2019 | 17 | 0.040 |
Why?
|
| Microsatellite Instability | 1 | 2019 | 1 | 0.040 |
Why?
|
| Nonsense Mediated mRNA Decay | 1 | 2019 | 1 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 34 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2018 | 14 | 0.040 |
Why?
|
| DNA Breaks | 1 | 2018 | 1 | 0.040 |
Why?
|
| Genome-Wide Association Study | 1 | 2018 | 4 | 0.040 |
Why?
|
| Genome | 1 | 2018 | 4 | 0.040 |
Why?
|
| Pedigree | 1 | 2017 | 7 | 0.040 |
Why?
|
| MRE11 Homologue Protein | 1 | 2017 | 1 | 0.040 |
Why?
|
| Acid Anhydride Hydrolases | 1 | 2017 | 1 | 0.040 |
Why?
|
| Neurofibromin 1 | 1 | 2017 | 1 | 0.040 |
Why?
|
| DNA Repair Enzymes | 1 | 2017 | 1 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2017 | 1 | 0.040 |
Why?
|
| Fanconi Anemia Complementation Group Proteins | 1 | 2017 | 1 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2017 | 2 | 0.040 |
Why?
|
| RNA Helicases | 1 | 2017 | 2 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2019 | 402 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2017 | 17 | 0.030 |
Why?
|
| Information Dissemination | 1 | 2017 | 12 | 0.030 |
Why?
|
| Consensus | 1 | 2017 | 32 | 0.030 |
Why?
|
| Registries | 1 | 2017 | 53 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2017 | 229 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 2015 | 9 | 0.030 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2016 | 62 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 45 | 0.030 |
Why?
|
| Cholesterol 7-alpha-Hydroxylase | 1 | 2001 | 1 | 0.010 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2001 | 1 | 0.010 |
Why?
|
| Cholestanetriol 26-Monooxygenase | 1 | 2001 | 1 | 0.010 |
Why?
|
| Steroid Hydroxylases | 1 | 2001 | 3 | 0.010 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2001 | 3 | 0.010 |
Why?
|
| Cholesterol | 1 | 2001 | 29 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2001 | 196 | 0.010 |
Why?
|